2 in 3 children Globally, with retinoblastoma die For $440 per child we will make retinoblastoma a zero death cancer and test a novel approach to health optimization

Retinoblastoma (RB) RB is cancer of the infant retina 8,000 RB cases annually worldwide with 70% mortality Complex care, large multidisciplinary teams, with poor communication No standard of care, doctor opinion selects treatment, uniquely failed evidence base Patient families have limited access to medical records

DEPICT HEALTH DEPICT HEALTH will index, and collect lifelong data from, every child diagnosed with retinoblastoma globally For each patient, DEPICT HEALTH will enhance communication across the circle of care, independent of geography Globally, data collated by DEPICT HEALTH will empower research, including machine learning, that will improve outcomes and ultimately eliminate deaths Retinoblastoma is a realistic pilot of this novel approach to healthcare optimization given that it is a rare neglected disease with public demand for evidence

FULL VIEW FOR LIFE

DEPICT HEALTH Enhances Communication Across the Circle of Care Family controls view-only access Lifelong data entry Circle of Care becomes a TEAM FAMILY controls view only access

Enhanced Communication Incentivizes Point-of-Care DEPICT HEALTH Data Entry

DEPICT HEALTH Will Be Deployed Using An Existing Network of RB Treatment Centres www.1rbw.org India and china Different social models

DEPICT HEALTH Governance Patients Participate Coded Data Research Steering Committee Direct Operations Committee Advise Working Groups Support oversight Sites circle of care Communicate by DEPICT HEALTH Machine Learning REAL WORLD evidence

DEPICT HEALTH Deploy DEPICT HEALTH $4.4 million to onboard 180 treatment centers Deploy DEPICT HEALTH $8.0 million to create and support 52,000 patient accounts Maintain DEPICT HEALTH $6.7 million for research, including machine learning Develop RB Evidence Base

Username: demo-user Password: Demo1234 DEPICT HEALTH http://depictrb.technainstitute.com Username: demo-user Password: Demo1234 On Internet cloud Secure standards Fully identified Coded data for research cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b cT2bN0M0H1* Group A cT1a Group D cT2b Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nature Reviews Disease Primers. 2015:15021. *Mallipatna A, Gallie BL, Chévez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual. Vol 8th Edition. New York, NY: Springer; 2017:819-831.

Retinoblastoma will be a zero death cancer Brenda Gallie, MD The International Retinoblastoma Consortium Toronto Canada